LivaNova PLC Announces Its Intent to Delist from London Stock Exchange
February 23 2017 - 1:05PM
Business Wire
LivaNova PLC (NASDAQ: LIVN; LSE: LIVN) (“LivaNova” or the
“Company”), a market-leading medical technology and innovation
company, today announced it applied for the voluntary cancellation
of its standard listing of ordinary shares with the United Kingdom
Listing Authority and to the London Stock Exchange (“LSE”) to
cancel trading of those shares. The Company’s decision was
primarily due to the low volume of its shares being traded on the
LSE. Trading of the Company’s shares on the LSE will cease at the
close of business on April 4, with the cancellation expected to
become effective at 8 a.m. GMT on April 5.
The Company will continue to serve its shareholders through its
listing on the NASDAQ Stock Market (“NASDAQ”), where today the vast
majority of trading in LivaNova shares occurs.
The Company is announcing this decision now to provide
sufficient time for shareholders who may be unable to hold shares
on NASDAQ to liquidate their holdings in an orderly manner.
Shareholders may continue to direct their broker to complete a
CREST Stock Withdrawal in order for their depository interests to
be cancelled and for book-entry interests in respect of the
underlying shares to be transferred from the Depository Trust
Company (“DTC”) participant account of Computershare to the account
of their designated DTC participant.
Shareholders wishing to ask further questions about this process
should contact Computershare Investor Services PLC at +44 0370 702
0000 or LivaNova’s Corporate Secretary at
Company.Secretariat@LivaNova.com. LivaNova’s corresponding RNS and
8-K filings are available at http://Investor.LivaNova.com.
About LivaNova
LivaNova PLC, headquartered in London, UK, is a global
medical technology company formed by the merger of Sorin S.p.A, a
leader in the treatment of cardiovascular diseases,
and Cyberonics Inc., a medical device company with core
expertise in neuromodulation. LivaNova transforms medical
innovation into meaningful solutions for the benefit of patients,
healthcare professionals and healthcare systems. The company
employs approximately 4,600 employees worldwide. With a presence in
more than 100 countries, LivaNova operates as three business
franchises: Cardiac Rhythm Management, Cardiac Surgery and
Neuromodulation, with operating headquarters in Clamart (France),
Mirandola (Italy) and Houston (U.S.A.), respectively.
LivaNova is listed on NASDAQ and listed on the Official
List of the UK’s Financial Conduct Authority and traded
on London Stock Exchange (LSE) under the ticker symbol
“LIVN.”
For more information, please visit www.LivaNova.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170223006293/en/
LivaNova PLC Investor Relations and MediaKaren
King, +1 (281) 228-7262Vice President, Investor Relations &
Corporate CommunicationsorDeanna Wilke, +1 (281)
727-2764Corporate External Communications
Managercorporate.communications@livanova.com
Livanova (LSE:LIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Livanova (LSE:LIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024